
News|Videos|April 8, 2026
7 Cardiology Headlines You Missed in March 2026
Author(s)Abigail Brooks, MA
Fact checked by: Ryan Livingston
March 2026 cardiology updates feature key ACC.26 data, new guidelines, and advances in PAH, AF, hypertension, and lipid management.
Advertisement
Advertisement
March delivered a wave of impactful updates in cardiology, with major trial readouts, regulatory progress, and new guideline recommendations shaping the evolving landscape of cardiovascular care, many of which were highlighted at the American College of Cardiology’s Annual Scientific Session (ACC.26). From pulmonary arterial hypertension (PAH) to atrial fibrillation and hypertrophic cardiomyopathy, the month showcased continued momentum in both therapeutic innovation and clinical strategy.
Related to this article

Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.

Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.

The FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.
Advertisement
Advertisement

